Oxford Biomedica (OXB) Competitors

Oxford Biomedica (LON:OXB) and Genus (LON:GNS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

Do analysts prefer OXB or GNS?

Oxford Biomedica presently has a consensus target price of GBX 558, suggesting a potential downside of 7.00%. Genus has a consensus target price of GBX 2,900, suggesting a potential upside of 14.62%. Given Genus' stronger consensus rating and higher possible upside, analysts clearly believe Genus is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Genus	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media favor OXB or GNS?

In the previous week, Oxford Biomedica had 3 more articles in the media than Genus. MarketBeat recorded 4 mentions for Oxford Biomedica and 1 mentions for Genus. Oxford Biomedica's average media sentiment score of 1.54 beat Genus' score of 0.96 indicating that Oxford Biomedica is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oxford Biomedica	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Genus	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, OXB or GNS?

Oxford Biomedica has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Comparatively, Genus has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500.

Do insiders & institutionals hold more shares of OXB or GNS?

32.4% of Oxford Biomedica shares are held by institutional investors. Comparatively, 63.4% of Genus shares are held by institutional investors. 41.9% of Oxford Biomedica shares are held by insiders. Comparatively, 0.7% of Genus shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Is OXB or GNS more profitable?

Genus has a net margin of 1.18% compared to Oxford Biomedica's net margin of -145.98%. Genus' return on equity of 1.41% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-145.98%	-202.50%	-12.67%
Genus	1.18%	1.41%	3.31%

Which has stronger earnings and valuation, OXB or GNS?

Genus has higher revenue and earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£151.21M	4.77	-£143.51M	-£36.22	-16.57
Genus	£672.80M	2.49	£7.87M	£28.90	87.54

Summary

Genus beats Oxford Biomedica on 10 of the 16 factors compared between the two stocks.